Media stories about Atossa Genetics (NASDAQ:ATOS) have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.6256469007485 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ATOS traded down $0.01 on Friday, reaching $0.42. 517,783 shares of the company’s stock were exchanged, compared to its average volume of 2,047,668. The firm has a market capitalization of $13.84, a PE ratio of -0.17 and a beta of 2.97. Atossa Genetics has a twelve month low of $0.22 and a twelve month high of $1.59.
Separately, Maxim Group initiated coverage on shares of Atossa Genetics in a research report on Friday, January 26th. They issued a “buy” rating and a $2.00 target price on the stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/atossa-genetics-atos-getting-positive-media-coverage-study-finds.html.
About Atossa Genetics
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.